Market Overview

UPDATE: Jefferies Raises PT to $41 on Bristol-Myers Squibb on Long-Term Growth Prospects

Related BMY
US Stock Futures Edge Lower Ahead Of Federal Budget
Morgan Stanley Downgrades Bristol-Myers On Valuation
Apple Leads the Charge as Earnings Season Heats Up (Fox Business)

Jefferies maintained Bristol-Myers Squibb (NYSE: BMY) with a Buy rating and raisd the price target from $39.00 to $41.00.

Jefferies said, "2013 will likely deliver several major catalysts that will shape the direction of Bristol-Myers' mid to long term growth. We believe that Eliquis will beat launch expectations providing meaningful earnings momentum, whilst several major R&D catalysts (anti-PD1 and Yervoy) further expand the PE multiple. We reiterate our Buy rating and have increased our PT to $41 (from $39)."

Bristol-Myers Squibb closed at $36.93 on Monday.

Latest Ratings for BMY

DateFirmActionFromTo
Dec 2014JefferiesMaintainsHold
Nov 2014Morgan StanleyDowngradesOverweightEqual-weight
Nov 2014JP MorganMaintainsOverweight

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters